Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat during the virtual event on February 12, 2025, at 1:20 pm ET.
Interested parties can access the webcast through a direct link or via the 'Events and Presentations' section of Fulcrum's investor relations website. The presentation recording will remain available for a minimum of 30 days following the event on the company's website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FULC declined 3.66%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 at 1:20 pm ET.
The webcast of the fireside chat will be accessible HERE and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
FAQ
When is Fulcrum Therapeutics (FULC) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access FULC's Oppenheimer Conference presentation?
How long will FULC's Oppenheimer Conference presentation be available for replay?
What is the format of FULC's participation in the Oppenheimer Healthcare Conference 2025?
Is the Oppenheimer Healthcare Conference 2025 featuring FULC an in-person or virtual event?
